• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
HTX
Click for more information
0.00% 0.1¢

HEALTHLINX LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
HTXChairman's Address to Shareholders11/10/10
HTXShareholder UpdatePRICE SENSITIVE01/10/10
HTXAgreement executed with Millipore for AGR2 researchPRICE SENSITIVE29/09/10
HTXAnnual Report to shareholders23/09/10
HTXNotice of Annual General Meeting/Proxy Form10/09/10
HTXExpansion of UK Collaborators for International OvPlex StudyPRICE SENSITIVE09/09/10
HTXOvPlex ovarian cancer diagnostic licensed for Israel marketPRICE SENSITIVE07/09/10
HTXOvPlex launched is Asia03/09/10
HTXBreach of listing rule 7.103/09/10
HTXAppendix 3B02/09/10
HTXSection 708A Notice02/09/10
HTXChange of Director's Interest Notice02/09/10
HTXSouth Korea OvPlex Study Commences for KFDA ApprovalsPRICE SENSITIVE01/09/10
HTXApp 4E and Annual Report 2010PRICE SENSITIVE24/08/10
HTXOvPlex launch in Singapore05/08/10
HTXSection 708A cleansing notice30/07/10
HTXAppendix 3B30/07/10
HTXAppendix 4C and commentaryPRICE SENSITIVE22/07/10
HTXClarifications and additional information regarding OvPlex07/07/10
HTXOvPlex now available from new central London location05/07/10
HTXChange of Director's Interest Notice02/07/10
HTXAppendix 3B02/07/10
HTXSection 708A cleansing notice30/06/10
HTXAppendix 3B30/06/10
HTXHealthLinx progress on prostate cancer diagnosticPRICE SENSITIVE22/06/10
HTXEthics approval obtained in South Korea for OvPlex studyPRICE SENSITIVE21/06/10
HTXHealthscope to distribute OvPlex ovarian cancer testPRICE SENSITIVE15/06/10
HTXMajor International Study Begins on OvPlex testPRICE SENSITIVE15/06/10
HTXVictorian Government delivers $750,000 for OvPlex study15/06/10
HTXStoneBridge completes placement App3B and Section 708A08/06/10
HTXAppendix 3B07/06/10
HTXSection 708A Cleansing Notice07/06/10
HTXStonebridge Securities undertake private placementPRICE SENSITIVE01/06/10
HTXAppendix 3B06/05/10
HTXSection 708A cleansing notice06/05/10
HTXSection 708A cleansing notuice04/05/10
HTXAppendix 3B04/05/10
HTXAppendix 4C - quarterlyPRICE SENSITIVE29/04/10
HTXOvPlex to be launched in Singapore in JulyPRICE SENSITIVE29/04/10
HTXAppendix 3B for exercise of ESOP options16/04/10
HTXS708A notice released again to correct issue price error16/04/10
HTXSection 708A cleansing notice12/04/10
HTXAppendix 3B12/04/10
HTXCancellation of unquoted options08/04/10
HTXAppendix 3B01/04/10
HTXSection 708A cleansing notice01/04/10
HTXAppendix 3B29/03/10
HTXSection 708A cleansing notice for exercise of options22/03/10
HTXAppendix 3B18/03/10
HTXIncreasing international recognition of HealthLinx18/03/10
HTXIntus establishes UK OvPlex Scientific Advisory Board15/03/10
HTXCleansing notice S708A04/03/10
HTXAppendix 3B04/03/10
HTXOption movements and Appendix 3B04/03/10
HTXAppendix 3B, top 20 and range for new quoted options class04/03/10
HTXAppendix 3Y relodged to correct date of change04/03/10
HTXMovements in directors holdings with App 3Ys and F60404/03/10
HTXSection 708A Cleansing Notice01/03/10
HTXAppendix 3B01/03/10
HTXOsixmedia interview with Nick Gatsios26/02/10
HTXSecond tranche of placement completed24/02/10
HTXOvPlex sales launch in UK on 25 February 2010PRICE SENSITIVE24/02/10
HTXAppendix 4D and Half Year Accounts to December 2009PRICE SENSITIVE18/02/10
HTXSamples secured for commencement of major OvPlex studyPRICE SENSITIVE17/02/10
HTXOvPlex diagnostic clinical trial receives UK ethics approvalPRICE SENSITIVE11/02/10
HTXClinical Science to publish manuscript on HTX005 biomarker10/02/10
HTXOvPlex awarded BioSpectrum Asia Product of the year05/02/10
HTXCleansing Statement03/02/10
HTXAppendix 3B03/02/10
HTXHealthLinx expands collaboration with Liverpool UniversityPRICE SENSITIVE22/01/10
HTXAppendix 4C - quarterlyPRICE SENSITIVE21/01/10
HTXShareholder updatePRICE SENSITIVE12/01/10
HTXUnquoted options lapsed04/01/10
HTXCleansing Notice Section 708A(6)31/12/09
HTXAppendix 3B31/12/09
HTXAppendix 3B23/12/09
HTXHealthLinx completes first tranche of Placement23/12/09
HTXAppendix 3B22/12/09
HTXNotice under section 708A04/12/09
HTXAppendix 3B04/12/09
HTXChange of Director's Interest Notice04/12/09
HTXAppendix 3B04/12/09
HTXSpire Healthcare agrees terms to process and market OvPlexPRICE SENSITIVE02/12/09
HTXStoneBridge Securities undertakes private placement of $1.1mPRICE SENSITIVE30/11/09
HTXTrading HaltPRICE SENSITIVE30/11/09
HTXResults of Meeting26/11/09
HTXAGM presentation slides26/11/09
HTXChairman's Address to Shareholders26/11/09
HTXMater Hospital ethics approval for HealthLinx OvPlex studyPRICE SENSITIVE23/11/09
HTXNotice under Section 708A(6) of the Corporations Act30/10/09
HTXAppendix 3B30/10/09
HTXAppendix 4C - quarterlyPRICE SENSITIVE29/10/09
HTXHealthlinx wins $750k Victorian government grantPRICE SENSITIVE29/10/09
HTXNotice of Annual General Meeting/Proxy Form26/10/09
HTXCollaborators confirmed for next generation OvPlex studyPRICE SENSITIVE23/10/09
HTXCancellation of unlisted options09/10/09
HTXChange of date for AGM06/10/09
HTXNotice under Section 708A(6) of the Corporations Act05/10/09
HTXAppendix 3B05/10/09
HTX$7.2m funding from New York based institutional investorPRICE SENSITIVE05/10/09
HTXChairman's Address to Shareholders
11/10/10
HTXShareholder Update
01/10/10PRICE SENSITIVE
HTXAgreement executed with Millipore for AGR2 research
29/09/10PRICE SENSITIVE
HTXAnnual Report to shareholders
23/09/10
HTXNotice of Annual General Meeting/Proxy Form
10/09/10
HTXExpansion of UK Collaborators for International OvPlex Study
09/09/10PRICE SENSITIVE
HTXOvPlex ovarian cancer diagnostic licensed for Israel market
07/09/10PRICE SENSITIVE
HTXOvPlex launched is Asia
03/09/10
HTXBreach of listing rule 7.1
03/09/10
HTXAppendix 3B
02/09/10
HTXSection 708A Notice
02/09/10
HTXChange of Director's Interest Notice
02/09/10
HTXSouth Korea OvPlex Study Commences for KFDA Approvals
01/09/10PRICE SENSITIVE
HTXApp 4E and Annual Report 2010
24/08/10PRICE SENSITIVE
HTXOvPlex launch in Singapore
05/08/10
HTXSection 708A cleansing notice
30/07/10
HTXAppendix 3B
30/07/10
HTXAppendix 4C and commentary
22/07/10PRICE SENSITIVE
HTXClarifications and additional information regarding OvPlex
07/07/10
HTXOvPlex now available from new central London location
05/07/10
HTXChange of Director's Interest Notice
02/07/10
HTXAppendix 3B
02/07/10
HTXSection 708A cleansing notice
30/06/10
HTXAppendix 3B
30/06/10
HTXHealthLinx progress on prostate cancer diagnostic
22/06/10PRICE SENSITIVE
HTXEthics approval obtained in South Korea for OvPlex study
21/06/10PRICE SENSITIVE
HTXHealthscope to distribute OvPlex ovarian cancer test
15/06/10PRICE SENSITIVE
HTXMajor International Study Begins on OvPlex test
15/06/10PRICE SENSITIVE
HTXVictorian Government delivers $750,000 for OvPlex study
15/06/10
HTXStoneBridge completes placement App3B and Section 708A
08/06/10
HTXAppendix 3B
07/06/10
HTXSection 708A Cleansing Notice
07/06/10
HTXStonebridge Securities undertake private placement
01/06/10PRICE SENSITIVE
HTXAppendix 3B
06/05/10
HTXSection 708A cleansing notice
06/05/10
HTXSection 708A cleansing notuice
04/05/10
HTXAppendix 3B
04/05/10
HTXAppendix 4C - quarterly
29/04/10PRICE SENSITIVE
HTXOvPlex to be launched in Singapore in July
29/04/10PRICE SENSITIVE
HTXAppendix 3B for exercise of ESOP options
16/04/10
HTXS708A notice released again to correct issue price error
16/04/10
HTXSection 708A cleansing notice
12/04/10
HTXAppendix 3B
12/04/10
HTXCancellation of unquoted options
08/04/10
HTXAppendix 3B
01/04/10
HTXSection 708A cleansing notice
01/04/10
HTXAppendix 3B
29/03/10
HTXSection 708A cleansing notice for exercise of options
22/03/10
HTXAppendix 3B
18/03/10
HTXIncreasing international recognition of HealthLinx
18/03/10
HTXIntus establishes UK OvPlex Scientific Advisory Board
15/03/10
HTXCleansing notice S708A
04/03/10
HTXAppendix 3B
04/03/10
HTXOption movements and Appendix 3B
04/03/10
HTXAppendix 3B, top 20 and range for new quoted options class
04/03/10
HTXAppendix 3Y relodged to correct date of change
04/03/10
HTXMovements in directors holdings with App 3Ys and F604
04/03/10
HTXSection 708A Cleansing Notice
01/03/10
HTXAppendix 3B
01/03/10
HTXOsixmedia interview with Nick Gatsios
26/02/10
HTXSecond tranche of placement completed
24/02/10
HTXOvPlex sales launch in UK on 25 February 2010
24/02/10PRICE SENSITIVE
HTXAppendix 4D and Half Year Accounts to December 2009
18/02/10PRICE SENSITIVE
HTXSamples secured for commencement of major OvPlex study
17/02/10PRICE SENSITIVE
HTXOvPlex diagnostic clinical trial receives UK ethics approval
11/02/10PRICE SENSITIVE
HTXClinical Science to publish manuscript on HTX005 biomarker
10/02/10
HTXOvPlex awarded BioSpectrum Asia Product of the year
05/02/10
HTXCleansing Statement
03/02/10
HTXAppendix 3B
03/02/10
HTXHealthLinx expands collaboration with Liverpool University
22/01/10PRICE SENSITIVE
HTXAppendix 4C - quarterly
21/01/10PRICE SENSITIVE
HTXShareholder update
12/01/10PRICE SENSITIVE
HTXUnquoted options lapsed
04/01/10
HTXCleansing Notice Section 708A(6)
31/12/09
HTXAppendix 3B
31/12/09
HTXAppendix 3B
23/12/09
HTXHealthLinx completes first tranche of Placement
23/12/09
HTXAppendix 3B
22/12/09
HTXNotice under section 708A
04/12/09
HTXAppendix 3B
04/12/09
HTXChange of Director's Interest Notice
04/12/09
HTXAppendix 3B
04/12/09
HTXSpire Healthcare agrees terms to process and market OvPlex
02/12/09PRICE SENSITIVE
HTXStoneBridge Securities undertakes private placement of $1.1m
30/11/09PRICE SENSITIVE
HTXTrading Halt
30/11/09PRICE SENSITIVE
HTXResults of Meeting
26/11/09
HTXAGM presentation slides
26/11/09
HTXChairman's Address to Shareholders
26/11/09
HTXMater Hospital ethics approval for HealthLinx OvPlex study
23/11/09PRICE SENSITIVE
HTXNotice under Section 708A(6) of the Corporations Act
30/10/09
HTXAppendix 3B
30/10/09
HTXAppendix 4C - quarterly
29/10/09PRICE SENSITIVE
HTXHealthlinx wins $750k Victorian government grant
29/10/09PRICE SENSITIVE
HTXNotice of Annual General Meeting/Proxy Form
26/10/09
HTXCollaborators confirmed for next generation OvPlex study
23/10/09PRICE SENSITIVE
HTXCancellation of unlisted options
09/10/09
HTXChange of date for AGM
06/10/09
HTXNotice under Section 708A(6) of the Corporations Act
05/10/09
HTXAppendix 3B
05/10/09
HTX$7.2m funding from New York based institutional investor
05/10/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.